Federal Circuit Affirms Exelixis Patents, Blocking MSN Generic Until 2030
EXEL sits 62% above its 52-week low of $33.755.
Summary
A Federal Circuit affirmance means MSN's generic cabozantinib cannot launch before January 15, 2030, protecting Exelixis' core revenue stream from near-term generic competition.
Key Events · Legal and Risk Events · EXEL
-
Federal Circuit Affirms Patent Validity
The U.S. Court of Appeals for the Federal Circuit affirmed the Delaware district court's judgment that U.S. Patent Nos. 11,091,439, 11,091,440, and 11,098,015 are not invalid.
-
MSN Generic Blocked Until 2030
Based on the appellate opinion, any final FDA approval of MSN's ANDA cannot be effective earlier than January 15, 2030, the expiration date of the three affirmed patents.
-
Fourth Patent Appeal Dismissed as Moot
The Federal Circuit dismissed MSN's appeal on U.S. Patent No. 11,298,349 (expiring February 10, 2032) and vacated the district court's decision on that issue.
-
Separate Litigation on Fifth Patent
Litigation involving U.S. Patent No. 12,128,039, which expires in February 2032, remains pending with trial scheduled to begin in November 2026.
Analysis · EXEL · Life Sciences
The Federal Circuit affirmed the validity of three key patents covering Exelixis' cabozantinib franchise, and the company disclosed that MSN's generic ANDA cannot receive final FDA approval before January 15, 2030. This removes a near-term generic threat to Exelixis' largest revenue driver. The court also dismissed MSN's appeal on a fourth patent expiring in 2032, leaving that patent's validity intact for now. A separate trial on a fifth patent (U.S. Patent No. 12,128,039) is scheduled for November 2026, so litigation risk is not fully resolved, but the 2030 date provides multi-year exclusivity clarity.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EXEL was trading at $54.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.5B. The 52-week trading range was $33.76 to $57.57. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.